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RESULTS 
A lymphocyte proliferative response was observed in cultures 
incorporating supernatants from cultured cells derived from 
perilesional tissues (median stimulation index 17.5, range 9.8-
36), in contrast to normal controls (median stimulation index 
1.3, range 0.97-1.8), p = 0.012, Mann-Whitney U test. Similar 
responses were observed with supernatants derived from both 
dermal papilla cells and interfollicular fibroblasts. TIns occurred 
irrespective of the source of responder cells and whether autologous or 
allogeneic combinations of dermal papilla cells and responder cells 
were used. No sigrllficant proliferative effect occurred in experiments 
using media from cultures derived from non-Iesional sites in alopecia 
arcata patients, or from normal control subjects. 
Significantly higher levels of IL-6 were detected in superna­
tants derived from perilesional dermal papilla cells (median level 
55 ng/ml, range 6.7-440) and in one cell line from a non­
lesional site than in those from normal dermal papilla cells 
(median level 3.0 ng/ml, range 2.6-8.5), p = 0.037, Mann­
Whitney U test. Biologic activity of the IL-6 in these superna­
tants was confirmed by neutralization with polyclonal goat 
anti-human IL-6 antiserum prior to performing the B9 assay. 
When the lymphocyte proliferation assay was repeated using 
supernatant samples pre-incubated for 1 h with nentralizing IL-6 
antiserum, there was only a small reduction in the proliferative 
response that was not significant (analysis of variance), suggest­
ing IL-6 was of only modest importance in inducing the 
mitogenic effect observed. In normal hair follicles, staining with 
the Mx antibodies was confined to the inner root sheath. 
Increased staining for Mx protein was observed within the hair 
follicles of perilesional alopecia areata tissues only. The distri­
bution of increased Mx expression was mainly in the keratino­
cytes of the outer root sheath and matrix of lesional anagen 
follicles but was mildly increased also in the dermal papilla 
compared to normal scalp tissue. 
DISCUSSION 
These experiments showed that cultured dermal papilla cells and 
interfollicular dermal fibroblasts from perilesional sites in alope­
cia areata release soluble factors that stimulate lymphocyte 
proliferation. Biologically significant levels of IL-6 were identi­
fied in dermal papilla cell culture supernatants derived from cells 
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up to passage 9 showing this property can be maintained for long 
periods ill vitro. The observation of Mx protein expression 
signifies local production of type I interferons in the hair follicle 
in alopecia areata. The antiproliferative activity of these cyto­
kines could well be relevant to the known pathodynamic 
disturbances of the hair-growth cycle including precipitation of 
catagen in newly involved follicles and failure to advance 
beyond the anagen III-IV stage in bald areas. 
The likely role of cytokines in the pathogenesis of alopecia areata 
can be summarized in two hypotheses. First, cytokine gene dys­
regulation is a possible mechanism for the primary disease abnor­
mality in alopecia arcata. Increased cytokine production by the 
dermal papilla of the hair follicle could explain the observed 
inlnbition of hair growth, disturbance of the hair-growth cycle, and 
the inflammatory response. In a patient with the appropriate 
genotype, the disease process could be triggered by diverse stimu li 
including infection, trauma, and stress, all of which have been 
implicated clinically. Alternatively, production of pro-inflammatory 
cytokines and chemoattractant factors by the dermal papilla may be 
central to the pathogenesis of alopecia areata, although not itself 
explaining the basic cause of the disease. The increased cytokine 
production found in alopecia areata may be a manifestation of a final 
common pathway of disturbances found in a variety of diseases. 
vVe are grattjitl to Dr. lillian A. Symolls altd Professor Gordon W. D,,g; SectiOlI of 
lVIolecular Medicine, Department of Mediciue & Pharmacology, Ultiversity of 
Sheffield for helpful discussions alld assistallce with the cytokille assays aud to Dr. 
lVIohammed S.K. AI'Abadie for techllical assistaHce. 
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some clinical iInprovement after treatment with anti-inflammatory 
agents, suggest an autoimmune component in AA. This presenta­
tion will describe pathogenic mechanisms and therapeutic strategies 
under development in other probable autoiInmune diseases that 
may be instructive in the understanding and possible treatment of 
AA. Two excellent review articles on this subject have been 
published recently by Steinman [1] and Miller and Karpus [2]. 
PATHOGENIC MECHANISMS 
In neurologic diseases such as experimental autoimmune encepha­
lomyelitis (EAE) and multiple sclerosis (MS), the pathogenic agent 
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is known (EAE) or thought (MS) to be an activated Thl-type cell 
specific for myelin antigen epitopes. Similarly, T cells directed 
against organ-specific antigens are thought to initiate inflammation 
in other diseases such as arthritis and diabetes. It is widely believed 
that the autoimmune process involves an initial exposure to some 
exogenous agent (e.g. , a latent, tissue-specific virus) that later, 
upon activation by stress or other causes, induces local damage that 
sensitizes virus-specific T cells, autoreactive T cells, or cross­
reactive specificities. These T cells, upon exceeding a critical 
threshold frequency, cross the blood-tissue barrier and initiate the 
inflammatory cascade after reactivation with viral or tissue antigens. 
Reactivation induces the release of pro-inflammatory cytokines 
such as interferon-y and tumor necrosis factor (TNI') that respec­
tively upregulate major histocompatibility complex (MHC) expres­
sion (and inflammatory potential) and target cell damage. Addi­
tional mononuclear cells, including monocytes and tissue 
macrophages, are recruited to the area and activated by lympho­
kines. The key elements to the development of chronic progressive 
disease appear to be the presence of persistent antigen in association 
with MHC class II molecules, and maintenance of a critical 
frequency of inflammatory T cells. The distinction between disease 
induced by T cells specific for autoantigens versus persistant viral 
antigens is not always clear. In the case of Theiler's murine 
encephalitis virus, clinical impairment and progressive demyelina­
tion are mediated by virus-specific T cells without detectable 
involvement of autoantigens. However, in organ-specific disease 
models, disease progression may be maintained entirely by antore­
active T cells. The identification of relevant target antigens is 
complicated, however, by "determinant spreading," that is, sensi­
tization to new pathogenic epitopes unmasked during the attack on 
the initiating antigens [3]. In AA, it is not as yet possible to clarifY 
the respective roles of viruses versus auto antigens in the pathogenic 
mechanism. 
THERAPEUTIC STRATEGIES 
Understanding of pathogenic mechanisms has led to both non­
specific and antigen-specific therapeutic approaches. A number of 
exciting new approaches that may have application to the treatment 
of AA are discussed below. 
Anti-TNF-O' Antibody Because of the key role of TNF-O' in 
arthritis, a chimeric anti-TNF-O' monoclonal antibody was injected 
into patients with rheumatoid arthritis, and was found to produce 
significant clinical improvement [4]. This approach might have 
immediate application to AA, because TNF-O' has been fonnd in 
inflamed follicles, and could be partly responsible for the abnor­
malities in dermal papilla cells. 
Agents Directed at the T-Cell Receptor (TCR) The over­
expression ofV{3S.2 by TCR specific for basic protein (BP) by H_2u 
mice with EAE allowed successful treatment with V{3S.2-specific 
monoclonal antibody [5,6]. The putative role ofT cells directed at 
SP as pathogenic agents in MS has led to an application of the 
T-cell vaccination principle first developed by Irun R. Cohen. The 
most elfective study in humans demonstrated that two to three 
injections of attenuated, autologous BP-specific T-cell clones could 
induce cytotoxic anti-idiotypic T cells that deleted BP-specific T 
cells from the periphery [7]. Our own studies utilized TCR CDR2 
peptides to induce anergy in encephalitogenic V{3S.2+ BP-reactive 
T cells and reverse EAE [S]. More recently, we showed that V{35.2 
and V{36.1 CDR2 peptides could significantly increase the fre­
quency of regulatory TCR peptide-specific T cells in MS patients, 
with a corresponding loss of BP reactivity, and possible clinical 
benefit [9]. Therapies directed against the TCR require knowledge 
of the target antigen, and are not yet applicable to AA, in which 
there is still no defined tissue-specific antigen. 
THERAPEUTIC STRATEGIES IN AUTOIMMUNITY llS 
Antigen-Driven Tolerance Tolerance induced to specific au­
to antigens represents the most selective approach for immunoregu­
lation. High-dose tolerance, induced by injecting antigen repeti­
tively, deleted BP-reactive T cells and ameliorated EAE [10]. 
Soluble MHC/ Ag complexes, made by combining encephalito­
genic epitopes of BP with soluble MHC class II restriction mole­
cules, provides specific activation of the TCR complex without 
co-stimulatory interactions. Tlus approach induced clonal anergy 
and could successfully treat EAE [11]. Recently, tlns concept was 
extended elegantly through the production of a soluble, recombi­
nant MHC II molecule linked covalently to a chosen peptide ligand 
112]. Similarly, antigen-presenting cells crosslinked chemically with 
crude central nervous system antigens anergized Thl cells and 
reduced the number and severity of relapses in EAE [13]. This 
technique has the advantage of not requiring knowledge of the 
specific target antigens within the alfected organ, and conceivably 
could be applied to AA using follicular extracts. A new and highly 
selective approach involves desih'lling altered peptide ligands that 
lninllc the T-cell determinant, but act as T-cell antagonists [14] . 
TCR antagonist peptides have been elfective in E..A.E [15], but have 
no application to AA until disease-associated epitopes can be 
identified. Orally induced tolerance protocols may induce clonal 
deletion or active suppression, and have been highly elfective for 
suppressing EAE [16,17] and subsequent trials in MS using orally 
administered bovine myelin inllibited BP responses with possible 
clinical benefit [IS]. Because the target autoantigen does not need 
to be known, tins approach may be applicable to AA. 
CONCLUSIONS 
There are four conclusions: growing knowledge of autoimmune 
disease mechanism allows novel intervention strategies; dilferent 
strategies have varying degrees of therapeutic potential, and com­
bination therapies may be useful; successful intervention will be 
necessary to establish the contribution of autoimmunity to patho­
genesis; and early intervention may prevent epitope spreading. 
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Abnormalities in the Ultrastructure of Melanocytes 
and the Outer Root Sheath of Clinically Normal 
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A subclinical condition of alopecia areata has been described [1], in which abnormalities seen in follicles from active alopecia areata were also found to some extent in follicles from clinically normal, that is non-balding, regions of alopecia areata scalps. Ultra­
structural examination of the hair follicles from non-balding regions 
of alopecia areata may reveal iInportant information about the 
changes involved and help indicate the etiology of the disease. 
Our previous investigations have identified abnormalities in the 
orientation of the cells of the dermal papilla [1] and evidence of 
ultrastructural abnormalities:j:§ within the cells and of the dermal 
papilla-epithelial junction in follicles from clinically normal areas of 
alopecia areata scalps . Melanocytes have been implicated in the 
etiology of alopecia areata and regrowing hairs are often white [2]; 
because abnormalities of melanocytes and an unusual outer root 
sheath distribution have been reported [3] we have extended oUI 
investigations to the melanocytes and epithelial components of the 
clinically normal follicle. 
We have compared the ultrastructure of clinically normal hair 
follicles with those of normal control scalps and active lesional edges to 
detem-rine the earliest changes at the ultrastructural level that may 
indicate the primary site of damage in d1e alopecia areata follicle. Scalp 
biopsies (4 mm) were taken from five nom1al controls and from six 
alopecia areata patients on first presentation. Patient biopsies were 
taken from d1e "active" edge of a patch of alopecia areata and a 
non-balding area within the same scalp bearing clinically normal 
terrn:inal hair. Control and non-balding region biopsies were taken 
from the occipito-parietal region. Individual follicles were microdis-
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sected, processed routinely for electron microscopy, and sectioned 
longitudinally through the middle plane of the follicle [4]. 
We have examined the ultrastructure of the hair bulb adjacent to 
the upper regions of the dermal papilla and found that all follicles 
contained melanocytes in the undifferentiated matrix and presumptive 
cortical regions. Nonnal follicles always had well developed melano­
cytes with melanosomes actively engaged in pigment transfer. In 
follicles from active alopecia areata regions melanosomes were gener­
ally absent or were small and poorly differentiated. Follicles from 
non-balding regions either contained well-formed melanocytes that 
were actively engaged in pigment transfer when there were few or no 
other signs of cellular degeneration or, conversely, showed varying 
degrees of abnormality of melanocyte distribution and morphology. 
We have not seen the unusual presence of melanocytes in the outer 
root sheaths as described by Tobin et al [3] in any follicles from alopecia 
areata, but we have noted other degenerative tendencies that corre­
spond well with the hypothesis of a sub-clinical condition in the 
disease. The cells of the outer root sheath were vacuolated to some 
extent in all follicles, outermost cells more so than inner. This 
vacuolation is attributed to loss of glycogen during preparation fiJr 
microscopy [5]. Non-balding region follicles resembled normal folli­
cles below about half papilla height. However, above half papilla 
height there was evidence of more extensive vacuolation and most 
noticeable was the marked presence of a fme granular deposit. In 
follicles from active lesions of alopecia areata vacuolation was even 
more pronounced, but no granular deposits were observed. 
Overall, degenerative trends in the structure, composition, and 
activity of melanocytes and melanosomes appeared to be dependent 
on the degree of activity of the disease. In the outer root sheath of 
non-balding region follicles cells were deteriorated and granular 
deposits were seen, whereas the inner epithelial cells appeared to be 
in quite good condition. The fine granular deposit observed in the 
follicles is probably glycogen. Small amounts were detected in 
some normal hair follicles , where it was located mainly on the inner 
edge of the innermost cells of the outer root sheath . However , in 
follicles from non-balding regions much larger amounts of granular 
deposit were distributed over a much greater area of the outer root 
sheath. A possible explanation for this increased content and 
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